The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer,
but new platinum agents have been very slow to enter the clinic. Recently, however, there …

The demonstration in the 1960s that cis-diamminedichloroplatinum (II), or cisplatin, inhibits
cellular division of Escherichia coli 1 led to the subsequent discovery that this simple …

In the course of examining the effect of electric fields on the growth of Escherichia coli cells,
a biological activity of platinum compounds was uncovered that led to the development of …

The discovery of cisplatin (cis-Pt (NH 3) 2 Cl 2) as an antineoplastic agent has focussed
attention on the rational design of metal complexes that can be potentially used in cancer …

Hasrat Ali was born in India and received his education at AMU Aligarh where he obtained
his Ph. D. in 1979 under the direction of Professor Shafiullah. After a short stay at Malti …

Since the discovery by Rosenberg and collaborators of the antitumor activity of cisplatin 35
years ago, three platinum antitumor drugs (cisplatin, carboplatin and oxaliplatin) have …

From the metal ions and metal compounds that are known to bind to DNA, many anticancer
Pt (II) and Ru (II)/Ru (III) compounds are known to have ligand-exchange kinetics in the …

Cisplatin was discovered to have cytotoxic properties in the 1960s, and by the end of the
1970s it had earned a place as the key ingredient in the systemic treatment of germ cell …

Transition-metal-based compounds constitute a discrete class of chemotherapeutics, widely
used in the clinic as antitumor and antiviral agents. Examples of established antitumor …

Thirty years after the onset of the first clinical studies with cisplatin, the development of
antineoplastic platinum drugs continues to be a productive field of research. This article …